



FOR IMMEDIATE RELEASE

Contact:
Susan Brady
Corporate Communications
617.621.8304
sbrady@ironwoodpharma.com

IRONWOOD PHARMACEUTICALS TO PRESENT AT J.P. MORGAN HEALTHCARE CONFERENCE

CAMBRIDGE, Mass., January 3, 2012 — Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present at the 30th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2012 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time at The Westin St. Francis in San Francisco. The presentation will be followed by a question and answer session that will begin at approximately 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.

A live webcast of both the presentation and the question and answer session will be accessible through the Investors section of Ironwood's website at www.ironwoodpharma.com. To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of each webcast will be available on Ironwood's website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agonist, is an investigational drug for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The efficacy portion of linaclotide's development program has been completed and supports the recently submitted NDA for both indications, as well as the MAA submission in Europe for the IBS-C indication. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.

SOURCE: Ironwood Pharmaceuticals, Inc.